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Abstract: Multiple sclerosis arises from a combination of genes and environment. It has abundant clinical symptoms, varied clinical
courses, and probably different histopathological subtypes. In the past 10 years, 6 therapies that partially treat MS have been
developed, and more are likely to be approved in the near future.
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Definition
Multiple sclerosis is a brain disease caused by white
blood cell invasion of the brain and spinal cord. The
invading T cells and monocytes spread outward from the
venules and cause demyelination and axonal disruption.

Clinical Subtypes of MS
Eighty-five percent of cases are relapsing/remitting
(Figure 1.A). Early in the disease, inflammation causes an
episode of neurological dysfunction followed by partial or
total recovery. These attacks usually occur every 2 years.
After about 10 years, the attacks become less frequent,
but MS transforms into a progressive disease, seemingly
neurodegenerative. The other 15% of patients have a
progressive disease from the outset (Figure 1.B). Once
the progressive phase is reached, the average rate of
decline is the same for the different subtypes of MS.

Clinical symptoms
Clinically, there is no “typical” patient because the MS
lesions are somewhat random and can involve any part of
the central nervous system. Thus, vision, brainstem,
sensory, motor, autonomic systems, and cognition can all

be affected. However, some areas of the brain do show a
predilection for MS plaques and the following
descriptions are for the most common events.
The optic nerves are involved in 20% of patients as
the first symptom. Loss is usually in the center of the
visual field with ill-defined margins, develops over hours
to days, is often associated with pain when the eye is
moved, and resolves in several weeks. This is to be
expected as inflammation develops diffusely, and slowly,
and it irritates pain-sensitive structures surrounding the
optic nerve (Figure 1.C). In contrast, in ischemic/embolic
optic nerve occlusion, a sudden curtain falls over half of
the visual field, there is an abrupt altitudinal step-off in
the visual field, pain is atypical, loss is permanent or only
for seconds, and patients are older with cardiovascular
risk factors.
Many
patients
develop
an
“internuclear
ophthalmoplegia”. On gaze to the right, for example, the
adducting left eye is unable to move completely to the
right and there is coarse nystagmus of the abducting right
eye. This is a classic finding in MS, and if it is bilateral in
a young person it is almost diagnostic of MS. It illustrates
an important principle in MS–the lesions have a
predilection for the ventricular system. The “medial
longitudinal fasciculus” (MLF) integrates these eye
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Figure 1. A. The course of MS is typically relapsing/remitting at first.
Attacks decrease in frequency and then symptoms
progressively worsen—“secondary progressive MS.” The
latter phase typically arises about 10 years after diagnosis,
when the patient is unable to walk more than 500 m.
B. Fifteen percent of MS patients have a progressive course
without
attacks—“primary
progressive
MS.”
C. New symptoms crescendo over hours to days, last for days
to weeks and then gradually disappear, sometimes
completely. This contrasts with cerebrovascular disease,
where symptoms appear suddenly and resolve quickly
(transient ischemic attack, TIA) or cause permanent
deficits (infarct).

movements, and connects the medial rectus portion of
the third nerve nucleus with the nuclei controlling the VI
nerve. The MLF runs along the brainstem aqueduct—part
of the ventricular system—and is therefore likely to be
interrupted by MS plaques.
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Spasticity, leg weakness, and bladder urgency are also
typical, especially in later, progressive forms of MS. This
illustrates another anatomic principle. Random plaques in
the spinal cord are likely to interrupt long tracts. Primary
progressive MS is predominantly a myelopathy, and over
many years relapsing/remitting MS often leads to
accumulation of spinal cord plaques.
Some generalized symptoms are commonly
overlooked, but are extremely important. Fatigue is the
number one complaint in MS. Eighty percent of patients
have generalized lassitude/tiredness/malaise or rapidly
tire after motor activity. These complaints are worse with
stress and heat. The external environment or internal
sources such as virus infections or the normal circadian
temperature elevation in the afternoon will increase body
temperature. This susceptibility to heat, termed Uhthoff’s
phenomenon, is from slowed conduction in heat-sensitive
demyelinated fibers.
Fatigue can be accompanied by weakness, but it is
different from motor weakness. MS fatigue is an
overwhelming lack of energy and feeling of exhaustion. It
is often continuous, and can also be triggered by minimal
effort. Motor weakness, spasticity, disturbed sleep-wake
cycles, effects of cytokines in the brain, and abnormalities
of the hypothalamic pituitary axis may contribute to
fatigue.
Mental function is reduced in 2 ways. Because of the
accumulation of subcortical and cortical plaques the
majority of patients have slowed cognition. This is often
undetectable in casual conversations, but is a major
source of disability. Secondly, as described by Charcot
150 years ago, some patients develop “pseudobulbar”
affect, laughing or crying at minor provocations.

Diagnostic tests
MRI is abnormal in 98+% of patients. T2 lesions are
small to medium-sized balls or spikes radiating out from
the ventricle and corpus callosum into the surrounding
white matter (“Dawson’s fingers”) (Figure 2.A). T1
lesions appear as black holes, often a result of permanent
axonal damage. Gadolinium-enhancing lesions last 2-6
weeks, like clinical attacks, but the correlation with
exacerbations is surprisingly low (r = 0.25, where r = 1
is a perfect correlation).
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degree of demyelination. A decrease in amplitude
indicates axonal damage, whereas delayed responses
suggest focal demyelination. These tests can determine
areas of demyelination, sometimes sub-clinical, and can
reflect the course of the disease.
Visual-evoked responses measure conduction from
the eyes to the occipital cortex, thus measuring more than
optic neuritis. They can be positive even if there is no
obvious visual loss. Brain stem auditory-evoked responses
reveal brain stem lesions, and measure conduction
horizontally through the brain. Somatosensory-evoked
potentials show abnormalities in the pathways from the
spinal cord to the cortex. In a small study that needs
confirmation, they correlated best with impaired position
sense. Vibration sense, the most common sensory
abnormality in MS, is abnormal because the 128 Hz signal
rapidly fatigues in demyelinated axons. Magnetic-evoked
motor potentials may be another sensitive measure of
spinal cord function in MS; techniques are under
development.
There are some other evoked responses that are used
at specialized laboratories. These include event-related
potentials (for cognitive evaluation), vestibular-evoked
myogenic potentials (saccular responses to loud acoustic
stimuli that are recorded from the ipsilateral
sternocleidomastoid muscle), and dichotic listening.

Prognosis

Figure 2. A. Typical T1-weighted MRI in MS with globular
periventricular lesions, some projecting out laterally from
the ventricles—“Dawson’s fingers.”
B. With vascular disease, in contrast, lesions are more likely
to appear in the centrum semiovale, and not next to the
ventricles. This is a case of CADASIL, a hereditary
disorder caused by vascular occlusions associated with a
non-demyelinating leukoencephalopathy.

Cerebrospinal fluid is abnormal in 95% of patients.
The most important component is 2 or more oligoclonal
bands, signifying chronic inflammation.
Evoked responses are functional tests that show the
speed of central neuronal conduction–this reflects the

The prognosis is better than popularly believed.
Women with MS have a normal lifespan; men die 3-5
years earlier than men without MS. Part of the
explanation is that MS patients are less likely to develop
cancer, presumably because they have “better” immune
systems than normal. Because this chronic disease begins
in young people, it results in years of inability to work
and care for the family, caretaker costs, and drug
expenses. The typical untreated patient will be using a
cane after 12 years. MS will have a significant effect on
the quality of life and on average will cost $2,200,000
over a lifetime.
Some factors augur a good prognosis—young,
female, relapsing/remitting, optic neuritis, sensory
symptoms, few MRI lesions, and a normal neurological
exam. Other factors are bad—male, progressive course,
and motor, brainstem, or cerebellar symptoms.
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north of Scotland; to 100/100,000 in the northern US
and Europe; to 30/100,000 in the southern US and
Europe. The incidence in Turkey is estimated to be 2050/100,000. (This number needs to be confirmed with
an epidemiologic study.) The yearly incidence of new
cases of MS in the US is 3.2/100,000.

Geographic Distribution
MS becomes more common with distance from the
equator. This is likely to arise from genetic and
environmental factors. Northern European genes confer
the most risk, Oriental genes the least. MS is rare in
American Indians, Turkmen, Uzbeks, Kazaks, Gypsies,
Native black Africans, and New Zealand Maoris. Migration
studies suggest that moving to an area of high incidence
before the age of 15 increases the risk of developing MS;
the converse is also true. After 15, exposure to a
presumed environmental factor has no effect. In support,
there is no evidence for conjugal transmission of MS.
What environmental agents might cause MS? Viruses
such as measles, EBV, HHV-6, adenoviruses, and
endogenous retroviruses have been suspected but are
now deemed unlikely by most investigators. In some
laboratories, chlamydia is found in more MS brains than
in controls, but the relevance is unclear. Antibodies to
many viruses, but also to ANA and other self-antigens, are
increased in MS. The excessive immune response in MS
may thus lead to false assumptions about causes of MS.
Figure 3. T2-weighted MRI of the spinal cord with a plaque in the left
dorsal column (lower right in figure). Only one segment is
involved. In transverse myelitis, the lesions typically affect
multiple contiguous segments. Accumulation of similar
lesions will compromise the long tracts of the spinal cord,
causing weakness, spasticity, bladder symptoms, and, as in
this case, reduced vibratory sensation.

Incidence
The average patient in the US is a 28-year-old woman
with higher than average income and intelligence. MS is
more common in women in Turkey; other demographic
characteristics await study. The onset ranges from late
teens into the 50s. Women tend to develop
relapsing/remitting MS a few years earlier than men, and
outnumber men in a 2:1 ratio. Men are more likely to
have progressive forms of MS.
The prevalence ranges from 190/100,000 people in
certain hot spots such as the Orkney and Shetland islands,
134

Heredity
No single gene causes MS. It is polygenic, and so close
relatives have a higher risk of developing MS. The relative
risk is 1 if no one in the family has MS, 25 in first-degree
relatives and dizygotic twins, and 200 in monozygotic
twins of an MS patient.

Susceptibility genes
The presence of MS is most strongly linked to HLADR2 in Northern Europeans, suggesting an immune
+
etiology for MS. In Japan, DR2 patients are most likely
to develop “Western” MS. However, DR2 Japanese
typically develop Devic’s disease, with involvement of the
optic nerves and spinal cord, but without disseminated
brain plaques. In the Mediterranean basin, other HLA
types are linked to MS. Since HLA genes control immune
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responses, it is not surprising that there are population
differences in some assays of immune cell cytokine
secretion. The clinical course or response to drug therapy
may also differ in subtle ways between populations. Also
important are subtypes of pathology (below).

Disease-modifying genes
The tempo of MS is affected by some genes that may
have nothing to do with susceptibility. These include
ApoE4 (faster progression), ciliary neurotrophic factor,
CNTF (worse MS when the gene is missing, as in 3% of
Europeans), and possibly IL-1 and chemokine receptors.

sometimes to front leg weakness and difficulty in
breathing. Symptoms begin to resolve after a week or so,
in clear parallel to an exacerbation of MS.
The inflammatory cells surrounding blood vessels are
initially myelin-reactive CD4 T cells, which then recruit
macrophages and nonspecific T cells. These cells cause
demyelination, but usually not as much demyelination as
in MS. Many of the drugs used in MS prevent EAE.
However, EAE is not a perfect model. CD8, and not CD4,
T cells correlate with damage in MS. MS patients’ cells
show minimal proliferation to myelin basic protein, the
usual inducer of EAE. Moreover, some drugs that prevent
EAE (e.g., interferon-γ, anti-TNF receptor antibodies)
actually worsen MS.

Role of environment
Infections
Although there is no clear evidence that any infective
agents cause MS, infections can trigger attacks. One of 3
upper respiratory infections causes an exacerbation in MS
patients, and the residual symptoms are more severe.
Bacterial infections double the rate of exacerbations,
including the bladder infections that are common in MS.
Smoking raises the attack rate by 60%. Immunization,
however, does not increase the rate of exacerbations, and
prevents immune-activating infections.

Nutrition
Epidemiologic and some dietary studies suggest that
fish and vegetable oils offer modest protection against
relapses. They can also help in controlling weight (see
below).

Pathology
An animal model, EAE
Experimental allergic encephalomyelitis (EAE) is an
animal model of MS. It drives much of the thinking about
immune and pathological mechanisms in the human
disease. EAE is induced by immunizing with brain
antigens (myelin basic protein, myelin-oligodendroglial
protein, and others) in a fine lipid emulsion of complete
Freund’s adjuvant. Ten days later, immune cells invading
the spinal cord and brain cause clinical
symptoms–ascending from a drooping tail, to hind leg
weakness and spasticity, bladder retention, and

MS pathology
In MS, immune cells invade the brain, where they
damage and destroy oligodendroglia and some neurons.
For unknown reasons, T cells and macrophages are
activated in the peripheral blood beforehand. These
activated cells express adhesion molecules, including VLA4, which they use to attach to the endothelial cells of the
post-capillary venules in the brain. The immune cells
secrete matrix metalloproteases that soften up the tight
junctions and cell membranes of the endothelial cells
(ECs) forming the blood-brain barrier (BBB). These
proteases help the immune cells to penetrate directly
through the ECs and underlying basement membrane.
Once inside the BBB, immune cells spread out from
the venule. A wave of CD4 T cells leads the way and
attracts CD8 T cells and monocytes. These cells secrete
toxic cytokines and also directly attack brain cells. Myelin
and myelin-forming cells are damaged and nearby
astrocytes hypertrophy. Neurons are also injured, and
many ultimately die.
Monocytes outnumber T cells by 8:1 in early lesions
and over 20:1 in chronic plaques. Monocytes and CD8
cells correlate with MRI damage and with the severity of
the lesion.
Typically there are 2 phases of MS. First, there is T
cell-driven inflammation with enhancing MRI lesions.
After approximately 10 years, MS evolves into a
degenerative/progressive disease, with few T cells but
many monocytes and less enhancement on the MRI.
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There are 4 pathological subtypes of MS, based on
biopsy and autopsy studies of scores of MS brains (Table
1). These include (I) perivenular demyelination with sharp
margins, activated macrophages in contact with myelin,
some early damage but later reappearance of
oligodendroglia, and lesions in the periventricular white
matter, some radiating outward from the ventricles on
MRI (Figure 2). Pattern (II) is similar to (I), but with
immunoglobulin and complement deposited at the site of
active myelin destruction. (I) and (II) resemble EAE.
Table 1. Four histopathological patterns in MS.
Pattern

Plaque Margins

IgG and
Complement

Oligodendroglia

I

Sharp

-

can remyelinate

II

Sharp

++

can remyelinate

III

Indistinct

-

++ death

IV

Sharp

-

++ death

The spectrum of demyelinating diseases
Demyelinating diseases range from
• Post-infectious or post-vaccinal encephalomyelitis,
of varying severity, but never to recur (the human
counterpart of EAE)
• Subclinical MS (detected at autopsy and possibly
equivalent in number to diagnosed cases)
• A single episode of optic neuritis or Transverse
myelitis
• Mild Relapsing-remitting MS (benign MS, possibly
5-10% of diagnosed cases)
• Typical Relapsing/remitting MS that evolves to
Secondary progressive disease as described in
Figure 1.A
• Primary progressive MS (Figure 1.B)
• Explosive onset of demyelination with death in
several years (Marburg’s variant)
• Acute disseminated encephalomyelitis
• Acute hemorrhagic leukoencephalitis of Weston
Hurst.

(III) Vague margins, vascular endothelial damage
sometimes causing thrombosis, and death of
oligodendroglia. (IV) Similar to (I), but with destruction
of oligodendroglia, seen most in primary progressive MS.
These patterns are unlikely to be 4 completely different
diseases, but rather reflect heterogeneity in genetic
background and environmental exposure.
The change over time and the different subtypes of
pathology suggest that the ideal therapy may differ in
early vs. late MS and between subtypes. For instance,
interferon-β (IFN-β), Copaxone, and chemotherapy all
work best in early relapsing/remitting MS. All are directed
at the early T cell-mediated inflammation. They have
minimal effect on progressive MS, suggesting that the
disease process is altered. Neurodegeneration might be
treated with a therapy that induces trophic factors for
oligodendrocytes and neurons. Current therapies have
theoretical benefit: “inflammatory cells” are sometimes
capable of producing trophic factors–IFN-β induces
leukemia inhibitory factor (LIF) and nerve growth factor
(NGF) and interleukin-10; Copaxone induces brainderived neurotrophic factor (BDNF). In contrast,
chemotherapy destroys all dividing cells and may
eliminate these beneficial subpopulations.
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Therapy of MS symptoms
Since there is no cure for MS, management of
symptoms should be a priority. Fatigue, cognitive loss,
psychological
problems,
spasticity,
autonomic
dysfunction, tremor, and pain are major problems with
MS. To eliminate or even to lessen these complaints could
make a patient’s life more comfortable.
Identifying the components of fatigue is important for
treatment. A sudden onset or increase in fatigue requires
a search for other systemic diseases. It should be
distinguished from emotional symptoms such as
depression; psychiatric referral may be helpful. Fatigue
affects cognition, social and family relationships, and
employment status. It is important to explain the possible
reasons for fatigue to the patient, family, and employer.
Work hours and environment should be modified to
prevent unemployment, which could worsen the
psychiatric and motor complaints. Amantadine, pemoline,
and recently modafinil, are effective for many patients
(Table 2). Modafinil promotes waking via the activation
of the histaminergic system. In placebo-controlled
studies, a 200 mg daily AM dose significantly improved

K. HAMAMCIO⁄LU, A. T. REDER

Table 2. Treatment of MS Symptoms.
Symptom

Drug

Dosage Range

Comment

Fatigue

Amantadine
Modafinil
Methylphenidate
Pemoline

100-400 mg/d
100-400 mg/d
5-20 mg/d
18.75-140 mg/d

P.O.,
P.O.,
P.O.,
P.O.,

1
1
1, 3
1, 3, 4

Pain

Gabapentin
Carbamazepine
Oxcarbazepine
Lamotrigine
Topiramate

300-1200 mg/d
200-1600 mg/d
300-1200 mg/d
100-400 mg/d
15-400 mg/d

P.O.,
P.O.,
P.O.,
P.O.,
P.O.,

1
1, 3, 4
1
1
1

Spasticity

Baclofen
Tizanidine
Diazepam
Clonidine
Dantrolene
Amitriptyline
Cyproheptadine
Dronabinol

5-80 mg/d
1-36 mg/d
2-20 mg/d
0.05-0.2 mg/d
25-100 mg/d
25-75 mg/d
4-36 mg/d
5-15 mg/d

P.O.,
P.O.,
P.O.,
P.O.,
P.O.,
P.O.,
P.O.,
P.O.,

I.T., 1
1, 2
1, 2, 3
patch, 1
1
1, 2
1, 2
1, 2

Cognitive Loss

Rivastigmine
Galantamine
Donepezil
Memantine

Depression

Sertraline
Citalopram
Amitriptyline
Fluoxetine

50-150 mg/d
20-60 mg/d
50-300 mg/d
10-40 mg/d

P.O.
P.O., 2
P.O., 2
P.O., 2

Bladder Dysfunctions

Oxybutynin
Tolterodine
Desmopressin
Terazosin

2.5-10 mg/d
2-8 mg/d
0.1-0.3 mg/d
1-5 mg/d

P.O.
P.O
nasal sp., 4
P.O.

Sexual Dysfunction

Sildenafil
Papaverine
Phentolamine

25-100 mg
30 mg
1 mg

*, 3
I.C.
I.C.

Clonazepam
Primidone
Propranolol
Isoniazid
Glutethimide

0.1-2 mg/d
25-250 mg/d
80-240 mg/d
800-1200 mg/d
750-1250 mg/d

P.O.,
P.O.,
P.O.,
P.O.,
P.O.,

Tremor

1:
2:
3:
4:

Should be titrated to lowest effective dose
Has sedative side effects
Should be given with caution
Needs follow up

3-6 mg/d
8-24 mg/d
5-10 mg/d
20 mg/d

P.O.:
I.C.:
I.T.:
*1h

P.O.
P.O., 1
P.O.
P.O.

1, 2
1
1, 4
1, 4
1

Orally
Intracorporeal
Intrathecal
before “sexual interaction”
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fatigue. Methylphenidate has value, but should be used
with caution. The combination of lofepramine (specific
noradrenaline reuptake inhibitor), L-phenylalanine (a
precursor of noradrenaline), and vitamin B12 injections
reduced fatigue in a very short period of time in one
series of reports, but needs replication. Aerobic exercise
is an important addition to drugs. Gentle exercise that
does not elevate body temperature, such as swimming or
short walks, is recommended.
Pain is a frequent complaint in MS patients. MS
plaques can directly cause trigeminal neuralgia,
Lhermitte’s sign, and optic neuritis. Spasticity,
osteoporosis, frozen joints, and immobility are secondary
causes of pain in MS. Trigeminal neuralgia and other
neuralgic pains respond to gabapentin, oxcarbazepine,
carbamazepine, lamotrigine, topiramate, non-steroidal
anti-inflammatory drugs, and misoprostol. Because of Na
channel redistribution in demyelinated axons, some
patients are very sensitive to Na channel blockers such as
carbamazepine.
Physical therapy is the best initial choice for treatment
of spasticity. Reducing spasticity also prevents the
symptoms of immobility such as frozen joints,
osteoporosis, and pain. Baclofen, a GABA agonist, and
tizanidine, an α2-adrenergic agonist, reduce spasticity
and pain during physical activity. These drugs should be
started at low doses and gradually increased to achieve
the best result with minimum side effects. Other agents
that can moderately reduce spasticity are
benzodiazepines, clonidine, gabapentin, tricyclic
antidepressants, cyproheptadine, and dantrolene. These
can be used alone or in combination. Cannabinoids may
improve spasticity and pain but they should be used with
caution.
When oral medication is not adequate, botulinum
toxin injections can be considered for small muscle
groups. Intrathecal baclofen administration with a radioprogrammable pump significantly lessens spasticity and
pain without systemic side effects. Intrathecal applications
of opioids such as morphine and fentanyl, or non-opioids
such as clonidine and bupivacaine, also provide pain relief.
For patients who do not respond to physiotherapy and
spasmolytic medication, the surgical choices are spinal
cord stimulation, tenotomy, myotomy, and posterior
rhizotomy.
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Cognitive loss may lead to inability to work, and
affects the whole course of MS and its treatment. Slowed
neuronal interaction impairs learning and memory, and
delays information processing—including physicianpatient interactions. It is sometimes hard to distinguish
from depressive symptoms and fatigue. This symptom
requires close support from family members and
caregivers. Rehabilitation is the most important step.
Rivastigmine, donepezil, and galantamine are oral
cholinesterase inhibitors that are at least as effective in
MS as in AD. Memantine, an antagonist of high
concentrations of glutamine, is also effective and possibly
neuroprotective.
Affective disorders, including depression, bipolar
disorder, and pathologic laughter and weeping, are
common but often overlooked in MS. IFNs could increase
depression in patients with pre-existing depression.
Although depression is seen among many chronically
disabled patients, strategically placed plaques in MS may
contribute to the pathophysiology of depression. Selective
serotonin reuptake inhibitors can be used for treatment
and also may reduce fatigue. Low doses of amitriptyline
have beneficial effects on pathologic laughing and
weeping. Successful treatment of affective disorders
improves compliance with other therapies.
Bladder dysfunction in MS affects both storing and
emptying, and treatment must be individualized for every
patient. Urgency and frequency characterize a hyperactive
bladder. Anticholinergic agents such as oxybutynin,
tolterodine, and propantheline bromide can be used for
this bladder hyperreflexia, and may synergize with an
anticholinergic tricyclic medication. If there are cognitive
problems, anticholinergic effects on the CNS should be
avoided, and tolterodine may be the best choice.
Desmopressin acetate nasal spray may prevent severe
nocturia that cannot be treated with fluid restriction or
long-lasting anticholinergics. Intravescicular botulunium
toxin injections can also reduce spasticity.
Excessive sphincter hyperreflexia can be treated with
anti-spasticity medication (baclofen, gabapentin) and/or
a-1 blockers (terazosin hydrochloride). These patients are
at risk for bladder infections because of high post-voiding
residual. Intermittent self-catheterization is the most
effective treatment for this. Patients with bladder
dysfunction should acidify urine with supplements of
cranberry juice or vitamin C (1-2 g/d) to prevent
infection.
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There are non-drug options for incontinence. Pelvic
muscle exercises and electrostimulation via a small rectal
or vaginal probe may strengthen weak muscles. Several
devices (short-term penile clamps for men and urethral
plugs for women) and diapers are available for
incontinence and dribbling. Risk for infection must be
considered while using external devices. Ablative surgery
of hyperactive sphincter should be avoided unless
medication and devices fail.
Sexual dysfunction can arise from MS plaques in the
cord or hypothalamus. However, psychological
components and side effects of medication always have to
be considered causes. Female sexual dysfunction should
not be ignored. Sildenafil has been used for both sexes. It
is effective in many men and some women. Topical drugs
such as nitroglycerin, minoxidil, and papaverine, and
intracavernosal papaverine, phentolamine, and alprostadil
could be used with caution for erectile dysfunction.
External vacuum devices and penile prostheses are other
options for treatment. Yohimbine, L-arginine, and
apomorphine have little effect on erectile dysfunction.
Expert urological, gynecological, and psychiatric
consultation should be used before and during the
treatment. The spouse should usually be informed about
the symptoms and treatment options.
Constipation is very common in MS patients.
Immobility, fluid restriction (patients drink less due to
bladder dysfunction), and side effects of anticholinergic
drugs all cause bowel problems. Management includes
increasing dietary fiber and fluid intake, caffeine, and
restriction of constipating medications. Physical therapy is
mandatory. Timed (daily) and unhurried defecation, and
stool softeners may be helpful. Anticholinergics reduce
fecal incontinence, but also cause constipation.
Tremor is from involvement of the cerebellum and its
outflow pathways. It is most likely to affect the arms, but
occasionally affects the legs, neck and trunk, causing
dysarthria, titubation, and gait ataxia. It is difficult to
treat. Clonazepam and benzodiazepines seem to lessen
tremor. Primidone, carbamazepine, glutethimide, and
isoniazid are anecdotally beneficial. In severe cases
stereotactic thalamotomy or thalamic electrostimulation
is effective, but less than in Parkinson’s disease, because
MS lesions are more diffuse.
Dry mouth and associated oral disease, due to side
effects of anticholinergic therapy and improper
nourishment, need dental care. Oral health impacts

positively on general health, and any infection in MS
activates the immune system. Obesity, a consequence of
immobility, can be controlled by a strict diet and physical
rehabilitation. Spasticity, immobility, sensory loss, and
incontinence are all risk factors for pressure sores. This
source of infection should be treated immediately, as
infections can trigger exacerbations of MS. Postural
changes, incontinence management, pressure-relieving
beds, and cessation of smoking can prevent pressure
sores. Osteoporotic bone fractures have been reported in
MS from steroid treatment and disuse, and immobility.
Management may include physical exercise, calcium and
vitamin-D, biphosphonates, and cessation of smoking.
The neurologist must constitute and conduct a team
to manage symptoms. Cognitive, physical, psychological,
and social problems require a coordinated approach by
experienced health and social services. Physical
rehabilitation including stretching, even yoga, is an
essential part of symptomatic management and
significantly alters disability. Patients always seek a
reliable neurologist. Capricious changing of physicians
should be avoided. Finally, 3 generations are affected by
a diagnosis of MS. Partners and other family members
may need emotional support, and effects on children
should not be ignored.

Therapy of MS
Steroids (glucocorticoids)
The management of acute attacks in MS traditionally
includes steroids. Glucocorticoids decrease MHC class II
protein expression and inhibit the transcription and
activity of pro-inflammatory cytokines (IL-1, 3,6, 8, TNFα, GM-CSF and IFN-γ), cause apoptosis of T cells and
decrease their activation. Glucocorticoids also inhibit
endothelial cell activity and stabilize the damaged BBB.
They shorten MS relapses, but do not impact long-term
prognosis.
For many decades, there has been no standard
protocol for steroid therapy of MS. The most popular
steroid protocol for MS is a daily 1 g methylprednisolone
(slow) IV infusion for 3-5 days. Oral tapering after a
high-dose IV course of steroids is advisable, based on
experience in animal models and other inflammatory
diseases. Most clinicians feel that after many courses of
glucocorticoids, there is less effect on relapses. Many
advise limiting the number of courses to 3 a year. Long139
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term steroids are not indicated for any form of MS. In
addition, there is no clear benefit of monthly or 3-4
monthly courses of oral steroids. High-dose oral
glucocorticoids probably have the same outcome as the IV
form (oral dexamethasone pills or methylprednisolone
liquid). Precautions against side effects of steroids include
avoiding aspirin and nonsteroidal drugs and
supplementation with potassium, vitamin D, and calcium.

Glatiramer acetate (Copaxone)
Glatiramer acetate is a random polymer of 4 amino
acids (L-glutamate, lysine, alanine, and tyrosine at a ratio
of 1.4:3.4:4.2:1). It binds strongly to the MCH and was
initially thought to block T cell recognition of brain
antigens because there are some similarities between
myelin basic protein and glatiramer. It is now thought
that it induces a Th1 to Th2 shift, and that these Th2 cells
home to the brain in search of MBP-like molecules. In the
CNS, the Th2 cells secrete anti-inflammatory cytokines.
Copaxone reduces the attack rate, appears to slow
progression, and reduces new enhancing MRI lesions, all
by 1/3. T1 black holes also tend to revert to more normal
appearing brain tissue after 6 months of therapy. It has
minimal side effects other than skin erythema and a rare
“immediate post-injection reaction,” where patients feel
impending doom for 10 min.

Interferon-β
IFN-β-1b and IFN-β-1a have multiple effects on
immunity, and the majority of the effects benefit MS.
Type I IFNs inhibit secretion of IFN-γ (a much different
Th1 cytokine that causes MS exacerbations), but induce
IL-10 in T cells (an anti-inflammatory Th2 cytokine). They
also inhibit migration of T cells through the endothelial
cells of the BBB, and may induce apoptosis of activated T
cells.
Betaferon, Avonex, and Rebif reduce the attack rate
and slow progression by 1/3. They reduce new enhancing
MRI lesions by 90%. As a result, T1 black holes tend not
to develop. IFN-β is most effective when used early; in
later purely progressive MS there is little change in
progression.
The main side effects are initial flu-like symptoms that
disappear after weeks and occasional lymphopenia and
elevated liver function tests. The subcutaneous forms
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cause skin erythema, and occasionally cause skin necrosis,
more so with Betaferon than with Rebif. However, severe
skin lesions with Betaferon have been reduced with the
new auto-injector device, and so the current incidence is
unknown.

Chemotherapy
In increasing rank of efficacy, azathioprine,
methotrexate, cyclophosphamide, and mitoxantrone
reduce exacerbation rates. They seem to be most
effective in early relapsing MS. This is counterbalanced by
the long-term risk of developing a malignancy, by liver
toxicity, and complications of immunosuppression. In
addition, mitoxantrone is limited to 2-3 years of
treatment because it is cardiotoxic.
Intravenous immunoglobulins have reduced the
relapse rate in Europe, but have had minimal effect in the
USA. The discrepancies may stem from different donor
pools or in the preparations themselves. Plasmapheresis
has no benefit in most patients.

New treatments and future drugs
Natalizumab (Tysabri, formerly Antegren) is a
monoclonal antibody that binds to VLA-4 antigen on verylate activated memory T cells, and prevents them from
sticking to brain endothelial cells. This monthly
intravenous drug reduced relapses by 50%, slowed
progression, and reduced MRI enhancement by 90% in a
6-month study. The relapse rate was slowed by 66% in
a phase III study. Tysabri, which received accelerated
approval from the FDA in November 2004, is suspended
because of 1 confirmed fatal case and 1 resolving case of
progressive multifocal leukoencephalopathy (PML) in MS
patients receiving this treatment in conjunction with IM
IFN-β1a. Effects of monotherapy with natalizumab are
under review.
Statins lower cholesterol, but also appear to reduce
inflammation. They dramatically reduce MHC class II
expression and Th1 immune responses, and inhibit EAE in
mice. They are safe in MS, and efficacy trials are planned.
One caution: in experimental studies, statins have both
pro-inflammatory and anti-inflammatory effects. The net
effect is not known. Effects on the IFN-β pathway are
likely.
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Peroxisome proliferator-activated receptor (PPAR-γ)
agonists (pioglitazone, rosiglitazone) are used to enhance
insulin effects in diabetes. They are also antiinflammatory and prevent EAE. MS trials are in the
formative stages.
Pregnancy prevents exacerbations as effectively as any
approved drugs (although this is canceled out by rebound
exacerbations after delivery). Estriol is one of the
hormones that rise during pregnancy. Estriol is less
thrombogenic than other estrogens. It inhibits EAE, and,
in a small study, it reduced exacerbations in
relapsing/remitting MS. A large trial is awaiting approval.
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